Timolol Maleate Eye Drops

Pharmacological action: Timolol maleate is a non-selective beta-adrenergic receptor blocker with no obvious endogenous sympathomimetic activity and local anesthetic effect, and no direct inhibitory effect on the myocardium. This product is timolol maleate eye drops, which can reduce intraocular pressure in patients with high intraocular pressure and normal people. The exact mechanism of reducing intraocular pressure is still unclear. Intraocular pressure recording and aqueous humor fluorescence photometry studies suggest that the intraocular pressure-lowering effect of this product is related to reducing aqueous humor production.

The main ingredients of this product and their chemical names are: The main ingredient is timolol maleate, and its chemical name is: (I)-1-(tert-butylamino)-3-[(4-morpholinyl-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate. Chemical structural formula: C13H24N4O3SC4H4O4, 432.49

This product is a colorless clear liquid.

It has a good effect of reducing intraocular pressure in primary open-angle glaucoma. For some secondary glaucoma, ocular hypertension, some primary angle-closure glaucoma and other glaucoma that are ineffective with other drugs and surgery, the addition of this product to the eye drops can further enhance the effect of reducing intraocular pressure.

Eye drops, 1 drop at a time, 1 to 2 times a day. If the intraocular pressure is under control, it can be changed to once a day. If other drugs are used, when switching to this product for treatment, the original drug should not be stopped suddenly. It should be gradually stopped from the second day of using this product.

1. The most common adverse reactions are burning and stinging of the eyes. 2. Cardiovascular system: bradycardia, arrhythmia. 3. Nervous system: dizziness, aggravation of myasthenia gravis symptoms, paresthesia, drowsiness, insomnia, nightmares, depression, mental confusion, hallucinations. 4. Respiratory system: bronchospasm, respiratory failure, dyspnea, nasal congestion, cough, upper respiratory tract infection. 5. Endocrine system: masking the symptoms of hypoglycemia in diabetic patients after taking insulin or hypoglycemic drugs.

1. Patients with bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease. 2. Sinus bradycardia, Ⅱ or Ⅲ degree atrioventricular block, obvious heart failure, cardiogenic shock. 3. Patients who are allergic to this product.

Precautions for children: The safety and efficacy of this product for children have not been determined. Precautions for pregnancy and lactation: The safety of this product for pregnant women has not been determined. This product can be detected in the breast milk of lactating women after eye drops. Because it has a variety of potential adverse reactions to breastfeeding infants, it is necessary to decide whether to stop breastfeeding or stop taking the drug based on the importance of the drops to the mother. Precautions for the elderly: Not yet clear.

1. Combination with epinephrine may cause pupil dilation. 2. It is not recommended to use two local beta-receptor blockers at the same time. 3. This product should be used with caution in combination with calcium channel antagonists, as it may cause atrioventricular conduction block, left ventricular failure and hypotension. For patients with impaired cardiac function, the two drugs should be avoided in combination. 4. Patients who are taking catecholamine-depleting drugs (such as reserpine) should be closely observed when using this product, as it may cause hypotension and significant bradycardia. 5. Combination of this product with digitalis and calcium channel antagonists can further prolong atrioventricular conduction time. 6. Combination of this product with quinidine can cause systemic beta-receptor disorders such as slowing of heart rate.

Keep away from light and store in a sealed container.

5 ml: 25 mg

24 months